Bright Minds Biosciences (Bright Minds Biosciences) EV-to-Revenue : (As of May. 21, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Bright Minds Biosciences's enterprise value is $0.36 Mil. Bright Minds Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Bright Minds Biosciences's EV-to-Revenue for today is .

The historical rank and industry rank for Bright Minds Biosciences's EV-to-Revenue or its related term are showing as below:

DRUG's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.21
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Bright Minds Biosciences's stock price is $1.10. Bright Minds Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Bright Minds Biosciences's PS Ratio for today is .

Bright Minds Biosciences EV-to-Revenue Historical Data

The historical data trend for Bright Minds Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences EV-to-Revenue Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

EV-to-Revenue

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Bright Minds Biosciences's EV-to-Revenue

For the Biotechnology subindustry, Bright Minds Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's EV-to-Revenue falls into.

Bright Minds Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Bright Minds Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.356	/	0
	=

Bright Minds Biosciences's current Enterprise Value is $0.36 Mil.
Bright Minds Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Bright Minds Biosciences (NAS:DRUG) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Bright Minds Biosciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.10	/	0
	=

Bright Minds Biosciences's share price for today is $1.10.
Bright Minds Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Bright Minds Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.